Takeda Gets FDA Nod For HyQvia In CIDP

The drug could become competitive with Argenx’s Vyvgart Hytrulo, but the market opportunity for the rare disease remains unclear due to continued diagnostic challenges.

Takeda announced the approval of HyQvia in CIDP • Source: Shutterstock

Takeda Pharmaceutical Co. Ltd.’s HyQvia (immune globulin infusion 10% [human]/recombinant human hyaluronidase) was approved by the US Food and Drug Administration for chronic inflammatory demyelinating polyneuropathy (CIDP), a rare disorder. The Japanese drug maker may soon find itself neck-and-neck in competition, however, against an up-and-coming European biotech company that produced positive data for a drug in the same disease last year.

How much of a market CIDP represents overall remains tough to tease out due to challenges with diagnosing the disease.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip